Related references
Note: Only part of the references are listed.PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis
G.V. Long et al.
ANNALS OF ONCOLOGY (2017)
COSMIC: somatic cancer genetics at high-resolution
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2017)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
Conor A. Bradley et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Proliferation of PD-1+CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients
Alice O. Kamphorst et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
A molecular portrait of microsatellite instability across multiple cancers
Isidro Cortes-Ciriano et al.
NATURE COMMUNICATIONS (2017)
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
Evan J. Lipson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer
Stephen K. Chia et al.
BREAST CANCER RESEARCH (2017)
The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis
Pedro N. Aguiar et al.
IMMUNOTHERAPY (2016)
Incidence and survival of sebaceous carcinoma in the United States
Raghav Tripathi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
PD-L1 expression in human cancers and its association with clinical outcomes
Xin Wang et al.
ONCOTARGETS AND THERAPY (2016)
PD-1 Blockade Expands Intratumoral Memory T Cells
Antoni Ribas et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Unusual presentation of metastatic sebaceous carcinoma and its response to chemotherapy: is genotyping a right answer for guiding chemotherapy in rare tumours?
V. Kumar et al.
CURRENT ONCOLOGY (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Eyelid Sebaceous Carcinoma: Clinicopathologic and Multiparametric Immunohistochemical Analysis That Includes Adipophilin
Frederick A. Jakobiec et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2014)
Synergistic Activity of the c-Met and Tubulin Inhibitor Tivantinib (ARQ197) with Pemetrexed in Mesothelioma Cells
Leticia G. Leon et al.
CURRENT DRUG TARGETS (2014)
Long-Term Remission of an Aggressive Sebaceous Carcinoma following Chemotherapy
Angela Orcurto et al.
CASE REPORTS IN DERMATOLOGY (2014)
Perilipin and adipophilin expression in sebaceous carcinoma and mimics
Chakib Boussahmain et al.
HUMAN PATHOLOGY (2013)
PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival
Evan J. Lipson et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman et al.
NATURE (2012)
The significance of DNA mismatch repair genes in the diagnosis and management of periocular sebaceous cell carcinoma and Muir-Torre syndrome
Brent J. Gaskin et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2011)
Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis
Christopher Lieu et al.
CLINICAL CANCER RESEARCH (2011)
Efficacy of c-Met inhibitor for advanced prostate cancer
William H. Tu et al.
BMC CANCER (2010)
Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors
Marlies H. G. Langenberg et al.
CLINICAL CANCER RESEARCH (2010)
A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
Joseph Paul Eder et al.
CLINICAL CANCER RESEARCH (2010)
A Retrospective Review of 1349 Cases of Sebaceous Carcinoma
Tina Dasgupta et al.
CANCER (2009)
Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines
Joseph D. Miller et al.
IMMUNITY (2008)
Share Paper
